Project preparatory phase:
- Develop the comprehensive financial management framework for the lead partner and assist with the overall Grant and Consortium Agreement closing process
- Support the set up of a Joint Research Unit
REVERT
starting date
January 1, 2020
ending date
December 31, 2024
funding
European Union’s Horizon 2020 research and innovation programme under grant agreement No 848098.
taRgeted thErapy for adVanced colorEctal canceR paTients
Innovative AI-based decision support system to improve therapies for patients with unresectable mCRC
| PROGRAMME | KEYWORDS | ROLE |
| Horizon 2020 | Artificial Intelligence, Predictive Algorythms, Biobanks, Oncology |
|
REVERT focuses on an innovative AI-based decision support system utilizing the experience and real-world data from several European general hospitals.
The main goal is to develop an improved and innovative model of combinatorial therapy that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable mCRC.
- 7 medical oncology units involved in the clinical trials
- 1 Predictive algorithm ‘trained’ through retrospective evaluation of the clinical profiles of patients
- Detailed analysis based on the study of consolidated data – which have been classified in the Revert database – on metastatic patients from European biobanks
Project implementation:
- Permanently align budget and operations
- Financial Reporting & Amendments management
- Monitor clinical studies, assess technoloygy readiness of the platform and identify follow-up opportunities
our role
latest news
No results found.
